GlassScriptPhysician profile
Ann R Davis
NPI 1528012846
$27,179.01
in general payments reported to CMS, 2019-2025
38 companies · $3,596 in 2025
The $3,596 reported for 2025 was more than what 90% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,603 · 2020: $1,699 · 2021: $2,388 · 2022: $3,307 · 2023: $3,705 · 2024: $3,883 · 2025: $3,596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,183.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $9,483.00 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $2,523.67 | 2019-2025 | Farxiga, Airsupra, Wainua |
| E.R. Squibb & Sons, L.L.C. | $2,445.83 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $1,528.61 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,363.01 | 2019-2025 | Jardiance |
| Pfizer INC. | $1,169.04 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $1,010.97 | 2019-2024 | Livalo, Seglentis |
| Janssen Pharmaceuticals, INC | $874.02 | 2019-2023 | Xarelto |
| Amarin Pharma, INC. | $795.32 | 2019-2022 | |
| Esperion Therapeutics, INC. | $624.41 | 2020-2025 | Nexletol |
| Novo Nordisk INC | $611.84 | 2022-2025 | Wegovy, Ozempic |
| Boston Scientific Corporation | $480.38 | 2019-2023 | Watchman Access System |
| Cvrx, INC. | $471.50 | 2022-2025 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $450.09 | 2022-2023 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $380.62 | 2023-2025 | Opsumit, Uptravi |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $255.08 | 2023-2025 | Amvuttra, Onpattro |
| Abbott Laboratories | $212.30 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Sanofi-Aventis U.S. LLC | $174.80 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $164.53 | 2019 | |
| Bridgebio Pharma, INC. | $148.23 | 2025 | Attruby |
| Atricure, INC. | $144.48 | 2023-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Cardiac Dimensions, INC. | $142.67 | 2024 | |
| Impulse Dynamics (USA) INC. | $141.87 | 2024 | Optimizer |
| Scpharmaceuticals INC. | $140.62 | 2024-2025 | |
| Lexicon Pharmaceuticals, INC. | $137.90 | 2023-2024 | Inpefa |
| Heartflow, INC. | $131.43 | 2019 | |
| Medtronic, INC. | $130.61 | 2025 | Symplicity G3 |
| Arbor Pharmaceuticals, INC. | $129.04 | 2019-2020 | |
| Kiniksa Pharmaceuticals, LTD. | $124.38 | 2021-2023 | Arcalyst |
| Phathom Pharmaceuticals, INC. | $124.01 | 2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $121.83 | 2025 | |
| Aimmune Therapeutics, INC. | $111.30 | 2025 | Zenpep |
| Daxor Corporation | $110.10 | 2024 | Bva-100 |
| Itamar Medical INC | $108.32 | 2022 | |
| Lilly USA, LLC | $88.92 | 2025 | Zepbound |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $79.72 | 2024-2025 | Lifevest |
| Kestra Medical Technology Services, INC. | $30.26 | 2023-2024 | Assure Wcd |
| Lantheus Medical Imaging, INC. | $14.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.